Savara Inc (NASDAQ:SVRA) has earned an average rating of “Hold” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.93.

SVRA has been the subject of a number of research analyst reports. Canaccord Genuity reduced their price target on shares of Savara from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, June 13th. BidaskClub lowered shares of Savara from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 14th. Zacks Investment Research lowered shares of Savara from a “buy” rating to a “hold” rating in a research report on Friday, May 17th. Evercore ISI set a $17.00 price objective on shares of Savara and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, LADENBURG THALM/SH SH lowered shares of Savara from a “buy” rating to a “neutral” rating and cut their price objective for the company from $21.00 to $3.00 in a research report on Thursday, June 13th.

In other Savara news, Director David A. Ramsay acquired 58,357 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were purchased at an average price of $2.37 per share, with a total value of $138,306.09. Following the completion of the transaction, the director now owns 64,685 shares in the company, valued at $153,303.45. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director David A. Ramsay acquired 40,215 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were acquired at an average cost of $2.37 per share, for a total transaction of $95,309.55. Following the transaction, the director now owns 23,570 shares of the company’s stock, valued at approximately $55,860.90. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 99,472 shares of company stock worth $235,758. Insiders own 6.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY acquired a new position in Savara during the first quarter valued at approximately $83,000. DekaBank Deutsche Girozentrale grew its holdings in Savara by 19.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 12,300 shares of the company’s stock valued at $141,000 after purchasing an additional 2,000 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Savara during the first quarter valued at approximately $116,000. Sullivan Bruyette Speros & Blaney LLC acquired a new position in Savara during the second quarter valued at approximately $38,000. Finally, Parametric Portfolio Associates LLC acquired a new position in Savara during the second quarter valued at approximately $59,000. 41.19% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ SVRA traded down $0.06 during mid-day trading on Friday, reaching $2.61. The company had a trading volume of 10,020 shares, compared to its average volume of 203,680. The stock has a fifty day moving average of $2.37 and a two-hundred day moving average of $6.28. The company has a debt-to-equity ratio of 0.22, a quick ratio of 12.61 and a current ratio of 12.61. The company has a market capitalization of $111.03 million, a price-to-earnings ratio of -2.03 and a beta of 0.21. Savara has a 12-month low of $2.11 and a 12-month high of $11.96.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. Sell-side analysts forecast that Savara will post -1.65 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.